Examine the role of statutory bodies like the Indian Pharmacopoeia Commission in ensuring drug quality and patient safety in India.

Drug quality and patient safety in India rest less on a single regulator than on a chain of specialised bodies. The Indian Pharmacopoeia Commission (IPC), Ghaziabad, under the Ministry of Health & Family Welfare, anchors this chain — setting prescribing standards and running the country's adverse-event monitoring machinery, while CDSCO enforces.

Setting standards for quality and rational use

• IPC publishes the National Formulary of India (NFI), meant "for the guidance of the members of the medical and pharmaceutical profession", selecting therapeutic agents by expert consensus and assisting the framing of national drug policies [1].
• The 7th Edition (NFI 2026), with a digital version, was released on 21 September 2026 by MoS Health Smt. Anupriya Patel — extending clinical decision support through e-health tools [2].
• Standard-setting is the upstream condition for enforcement: CDSCO's quality action is only as strong as the benchmark it tests against.

Institutionalising patient safety

• The Pharmacovigilance Programme of India (PvPI) began in July 2010 under CDSCO; its National Coordinating Centre shifted from AIIMS New Delhi to IPC in April 2011 [3].
• IPC now runs three verticals — pharmacovigilance (drugs), materiovigilance (devices) and the newly announced Biovigilance Programme of India (BvPI) for organ/tissue transplantation and biologicals [2].
• BvPI answers a real gap: transplants rose from under 5,000 (2013) to nearly 20,000 in 2025, with only about 18% from deceased donors [4].

Persisting institutional gaps

• Reporting remains largely voluntary — sixteen years on, PvPI still needs annual campaigns urging doctors to report [5].
• Traceability is incomplete: IPC's vigilance pipeline [2] and NOTTO's retrieval-transplant network [4] lack a shared donor identifier, so donor-to-recipient clusters may go undetected.

IPC thus converts scattered quality rules into a coherent safety ecosystem. Attaching a statutory reporting duty — usable under the Transplantation of Human Organs and Tissues Act, 1994 — with confidential reporting and feedback to reporters would complete it, advancing the patient-safety pillar of universal health coverage and SDG-3.